Drug Type Nanobody |
Synonyms |
Target |
Mechanism IL-5 inhibitors(Interleukin-5 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Churg-Strauss Syndrome | Preclinical | CN | 15 Mar 2024 | |
Hypereosinophilic Syndrome | Preclinical | CN | 15 Mar 2024 |